Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) announced that it acquired a portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain and dermatology categories from Ducere Pharma. The brands acquired include Doans, Bufferin, Nupercainal ointmnent, Cruex Nail gel, Comtrex and Myoflex.
Dr. Reddy’s plans to ramp up sales and marketing efforts for these brands and will focus on their expansion into existing and new market channels.
Through this acquisition, the company expects to foray into the branded consumer health space.
We note that Dr. Reddy’s is currently facing challenging conditions. Revenues are being hurt by persisting macroeconomic issues in some territories in emerging markets (comprising Russia, the Commonwealth of Independent States, Romania and rest of the world including Venezuela). Moreover, the Venezuela market remains weak, which will continue to impact the top line in the upcoming quarters.
As a result, the company is looking to add strategic assets to its portfolio in order to offset the impact of the aforementioned factors. Previously, the company had acquired UCB’s (UCBJF - Free Report) established products business in India, Nepal, Sri Lanka and Maldives in a transaction to expand its footprint in the fast growing areas of dermatology, respiratory and pediatric products. Meanwhile, Dr. Reddy’s is collaborating with Curis for the discovery, development and commercialization of small-molecule antagonists for immuno-oncology and precision oncology targets.
Dr. Reddy’s currently has a Zacks Rank #5 (Strong Sell). A couple of favorably placed stocks in the health care sector are Abbott Laboratories (ABT - Free Report) and Johnson & Johnson (JNJ - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) announced that it acquired a portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain and dermatology categories from Ducere Pharma. The brands acquired include Doans, Bufferin, Nupercainal ointmnent, Cruex Nail gel, Comtrex and Myoflex.
Dr. Reddy’s plans to ramp up sales and marketing efforts for these brands and will focus on their expansion into existing and new market channels.
Through this acquisition, the company expects to foray into the branded consumer health space.
We note that Dr. Reddy’s is currently facing challenging conditions. Revenues are being hurt by persisting macroeconomic issues in some territories in emerging markets (comprising Russia, the Commonwealth of Independent States, Romania and rest of the world including Venezuela). Moreover, the Venezuela market remains weak, which will continue to impact the top line in the upcoming quarters.
As a result, the company is looking to add strategic assets to its portfolio in order to offset the impact of the aforementioned factors. Previously, the company had acquired UCB’s (UCBJF - Free Report) established products business in India, Nepal, Sri Lanka and Maldives in a transaction to expand its footprint in the fast growing areas of dermatology, respiratory and pediatric products. Meanwhile, Dr. Reddy’s is collaborating with Curis for the discovery, development and commercialization of small-molecule antagonists for immuno-oncology and precision oncology targets.
Dr. Reddy’s currently has a Zacks Rank #5 (Strong Sell). A couple of favorably placed stocks in the health care sector are Abbott Laboratories (ABT - Free Report) and Johnson & Johnson (JNJ - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RDY - FREE
Get the latest research report on ABT - FREE
Get the latest research report on JNJ - FREE
Get the latest research report on UCBJF - FREE